Volume | 534,078 |
|
|||||
News | (1) | ||||||
Day High | 2.395 | Low High |
|||||
Day Low | 2.31 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Adicet Bio Inc | ACET | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.33 | 2.31 | 2.395 | 2.35 | 2.33 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,719 | 534,078 | US$ 2.35 | US$ 1,256,995 | - | 1.10 - 7.50 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:33:53 | formt | 600 | US$ 2.33 | USD |
Adicet Bio Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
98.42M | 43.16M | - | 24.99M | -69.79M | -1.62 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Adicet Bio News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACET Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.14 | 2.395 | 2.02 | 2.16 | 950,213 | 0.19 | 8.88% |
1 Month | 2.38 | 2.54 | 1.88 | 2.21 | 1,535,200 | -0.05 | -2.10% |
3 Months | 2.00 | 3.77 | 1.88 | 2.70 | 1,873,955 | 0.33 | 16.50% |
6 Months | 1.45 | 3.77 | 1.10 | 2.44 | 1,090,386 | 0.88 | 60.69% |
1 Year | 5.89 | 7.50 | 1.10 | 2.80 | 882,987 | -3.56 | -60.44% |
3 Years | 13.10 | 21.87 | 1.10 | 8.38 | 636,741 | -10.77 | -82.21% |
5 Years | 0.1557 | 21.87 | 0.1306 | 8.22 | 582,372 | 2.17 | 1,396.47% |
Adicet Bio Description
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. |